1 131

Cited 9 times in

Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study

 Sung Yong Oh  ;  Won Seog Kim  ;  Jin Seok Kim  ;  Seok Jin Kim  ;  Suee Lee  ;  Dae Ho Lee  ;  Jong-Ho Won  ;  In Gyu Hwang  ;  Min Kyoung Kim  ;  Soon Il Lee  ;  Yee Soo Chae  ;  Deok-Hwan Yang  ;  Hye Jin Kang  ;  Chul Won Choi  ;  Jinny Park  ;  Hyo Jung Kim  ;  Jung Hye Kwon  ;  Ho Sup Lee  ;  Gyeong-Won Lee  ;  Hyeon Seok Eom  ;  Jae-Yong Kwak  ;  Cheolwon Suh  ;  Hyo-Jin Kim 
 CANCER SCIENCE, Vol.101(11) : 2443-2447, 2010 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Child ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Lymphoma, B-Cell, Marginal Zone/drug therapy* ; Lymphoma, B-Cell, Marginal Zone/pathology ; Lymphoma, B-Cell, Marginal Zone/therapy ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Rituximab ; Treatment Outcome ; Young Adult
Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2%). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%). Median time to progression (TTP) was 2.4years (95% CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5% and 79.8%, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P=0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[-]). The CTx-R(+) group showed better responses than the CTx-R(-) group (83.9%versus 54.8%, P=0.026). However, no differences in TTP duration were detected (P=0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.